GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » Cost of Goods Sold

Broncus Holding (HKSE:02216) Cost of Goods Sold : HK$15.51 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding Cost of Goods Sold?

Broncus Holding's cost of goods sold for the six months ended in Jun. 2024 was HK$5.86 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2024 was HK$15.51 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Broncus Holding's Gross Margin % for the six months ended in Jun. 2024 was 79.75%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Broncus Holding's Inventory Turnover for the six months ended in Jun. 2024 was 0.17.


Broncus Holding Cost of Goods Sold Historical Data

The historical data trend for Broncus Holding's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding Cost of Goods Sold Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cost of Goods Sold
Get a 7-Day Free Trial 5.84 16.76 16.33 23.65 15.49

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 10.45 9.46 14.21 5.86 9.66

Broncus Holding Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$15.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Broncus Holding  (HKSE:02216) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Broncus Holding's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(28.928 - 5.857) / 28.928
=79.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Broncus Holding's Inventory Turnover for the six months ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Broncus Holding Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Broncus Holding's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Broncus Holding Business Description

Traded in Other Exchanges
N/A
Address
No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Executives
Xu Hong 2101 Beneficial owner
Zi Zhenjun
Xin Nuo Tong Investment Limited 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qm12 Limited 2101 Beneficial owner
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Computershare Hong Kong Trustees Limited 2301 Trustee
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited 2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines